Wade Iams, MD

Wade Iams, MD, says the guidance has changed on what to do when a ROS1 result lands after chemoimmunotherapy has already started.

Wade Iams, MD, says adding RNA-based next-generation sequencing (NGS) to DNA-based NGS identifies about 15% more patients with actionable fusions, and urges clinicians to confirm whether the panel they ordered includes RNA at all, since the report rarely makes that obvious.